ethosuximide ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
1087 77-67-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • ethosuximide
  • ethosuxide
  • etosuximid
  • 3-Methyl-3-ethylsuccinimide
An anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures.
  • Molecular weight: 141.17
  • Formula: C7H11NO2
  • CLOGP: 0.40
  • LIPINSKI: 0
  • HAC: 3
  • HDO: 1
  • TPSA: 46.17
  • ALOGS: -0.15
  • ROTB: 1

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
1.25 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 39.20 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 25 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 118.30 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 93 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
Nov. 2, 1960 FDA PARKE DAVIS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Seizure 127.57 43.28 62 1282 117812 50485968
Multiple-drug resistance 116.55 43.28 25 1319 3289 50600491
Aplastic anaemia 110.23 43.28 28 1316 7675 50596105
Drug ineffective 96.41 43.28 112 1232 819221 49784559
Petit mal epilepsy 94.38 43.28 21 1323 3268 50600512
Oropharyngeal oedema 85.30 43.28 13 1331 243 50603537
Generalised tonic-clonic seizure 80.05 43.28 29 1315 26281 50577499
Intellectual disability 77.07 43.28 14 1330 780 50603000
Suicidal behaviour 62.01 43.28 14 1330 2320 50601460
Macroglossia 53.86 43.28 10 1334 628 50603152
Status epilepticus 53.09 43.28 18 1326 13388 50590392

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Petit mal epilepsy 106.76 52.59 24 1115 2698 29570690
Drug ineffective 98.06 52.59 92 1047 363078 29210310
Seizure 88.98 52.59 51 1088 93072 29480316
Multiple-drug resistance 83.09 52.59 21 1118 3879 29569509
Myoclonic epilepsy 81.03 52.59 16 1123 959 29572429
Tonic convulsion 57.79 52.59 12 1127 924 29572464

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Petit mal epilepsy 228.57 40.08 49 2160 4983 64491540
Multiple-drug resistance 163.02 40.08 39 2170 6463 64490060
Seizure 148.88 40.08 84 2125 166808 64329715
Drug ineffective 121.42 40.08 145 2064 840102 63656421
Generalised tonic-clonic seizure 121.17 40.08 47 2162 39810 64456713
Aplastic anaemia 90.80 40.08 29 2180 13891 64482632
Oropharyngeal oedema 82.02 40.08 13 2196 242 64496281
Status epilepticus 63.81 40.08 25 2184 21638 64474885
Myoclonic epilepsy 63.63 40.08 14 2195 1594 64494929
Intellectual disability 58.26 40.08 12 2197 998 64495525
Suicidal behaviour 55.48 40.08 14 2195 2873 64493650
Benzodiazepine drug level decreased 52.44 40.08 7 2202 35 64496488
Cerebellar atrophy 51.83 40.08 11 2198 1057 64495466
Tonic convulsion 50.82 40.08 12 2197 1869 64494654
Drug interaction 49.12 40.08 61 2148 362022 64134501
Macroglossia 46.13 40.08 10 2199 1062 64495461
Epilepsy 44.21 40.08 22 2187 33509 64463014
Social avoidant behaviour 40.30 40.08 12 2197 4545 64491978

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N03AD01 NERVOUS SYSTEM
ANTIEPILEPTICS
ANTIEPILEPTICS
Succinimide derivatives
ATC N03AD51 NERVOUS SYSTEM
ANTIEPILEPTICS
ANTIEPILEPTICS
Succinimide derivatives
FDA PE N0000008486 Decreased Central Nervous System Disorganized Electrical Activity
CHEBI has role CHEBI:35623 anticonvulsants
CHEBI has role CHEBI:38215 calcium channel blockers
CHEBI has role CHEBI:176497 geroprotectors
MeSH PA D000927 Anticonvulsants
MeSH PA D002491 Central Nervous System Agents
FDA EPC N0000175753 Anti-epileptic Agent

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Absence seizure indication 79631006
Suicidal thoughts contraindication 6471006
Mood swings contraindication 18963009
Depressive disorder contraindication 35489007
Systemic lupus erythematosus contraindication 55464009 DOID:9074
Kidney disease contraindication 90708001 DOID:557
Disease of blood AND/OR blood-forming organ contraindication 191124002 DOID:74
Acute intermittent porphyria contraindication 234422006 DOID:3890
Disease of liver contraindication 235856003 DOID:409
Neutropenic disorder contraindication 303011007 DOID:1227




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.31 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Voltage-dependent T-type calcium channel subunit alpha-1G Ion channel BLOCKER WOMBAT-PK CHEMBL

External reference:

IDSource
4018631 VUID
N0000146944 NUI
D00539 KEGG_DRUG
4018631 VANDF
C0015043 UMLSCUI
CHEBI:4887 CHEBI
CHEMBL696 ChEMBL_ID
DB00593 DRUGBANK_ID
D005013 MESH_DESCRIPTOR_UI
3291 PUBCHEM_CID
1077 INN_ID
7182 IUPHAR_LIGAND_ID
5SEH9X1D1D UNII
4135 RXNORM
4199 MMSL
4701 MMSL
d00227 MMSL
001631 NDDF
387244008 SNOMEDCT_US
44790008 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Zarontin HUMAN PRESCRIPTION DRUG LABEL 1 0071-0237 CAPSULE 250 mg ORAL NDA 19 sections
Zarontin HUMAN PRESCRIPTION DRUG LABEL 1 0071-2418 SOLUTION 250 mg ORAL ANDA 19 sections
Zarontin HUMAN PRESCRIPTION DRUG LABEL 1 0071-2418 SOLUTION 250 mg ORAL ANDA 19 sections
ETHOSUXIMIDE HUMAN PRESCRIPTION DRUG LABEL 1 0121-0670 SOLUTION 250 mg ORAL ANDA 18 sections
ETHOSUXIMIDE HUMAN PRESCRIPTION DRUG LABEL 1 0121-0670 SOLUTION 250 mg ORAL ANDA 18 sections
ETHOSUXIMIDE HUMAN PRESCRIPTION DRUG LABEL 1 23155-532 CAPSULE 250 mg ORAL ANDA 17 sections
Ethosuximide HUMAN PRESCRIPTION DRUG LABEL 1 42806-711 CAPSULE 250 mg ORAL ANDA 18 sections
Ethosuximide HUMAN PRESCRIPTION DRUG LABEL 1 59762-2250 CAPSULE 250 mg ORAL NDA AUTHORIZED GENERIC 19 sections
Ethosuximide HUMAN PRESCRIPTION DRUG LABEL 1 59762-2350 SOLUTION 250 mg ORAL ANDA 19 sections
Ethosuximide HUMAN PRESCRIPTION DRUG LABEL 1 61748-024 SOLUTION 250 mg ORAL ANDA 17 sections
Ethosuximide HUMAN PRESCRIPTION DRUG LABEL 1 61748-025 CAPSULE 250 mg ORAL ANDA 19 sections
Ethosuximide HUMAN PRESCRIPTION DRUG LABEL 1 61748-025 CAPSULE 250 mg ORAL ANDA 19 sections
Ethosuximide HUMAN PRESCRIPTION DRUG LABEL 1 63629-8005 CAPSULE, LIQUID FILLED 250 mg ORAL ANDA 18 sections
ETHOSUXIMIDE HUMAN PRESCRIPTION DRUG LABEL 1 64380-878 CAPSULE 250 mg ORAL ANDA 12 sections
ETHOSUXIMIDE HUMAN PRESCRIPTION DRUG LABEL 1 64380-878 CAPSULE 250 mg ORAL ANDA 12 sections
ethosuximide HUMAN PRESCRIPTION DRUG LABEL 1 68382-443 CAPSULE 250 1 ORAL ANDA 17 sections
Ethosuximide HUMAN PRESCRIPTION DRUG LABEL 1 69387-108 CAPSULE, LIQUID FILLED 250 mg ORAL ANDA 19 sections
Ethosuximide HUMAN PRESCRIPTION DRUG LABEL 1 69452-152 CAPSULE, LIQUID FILLED 250 mg ORAL ANDA 19 sections
ETHOSUXIMIDE HUMAN PRESCRIPTION DRUG LABEL 1 71335-1763 CAPSULE 250 mg ORAL ANDA 12 sections
ETHOSUXIMIDE HUMAN PRESCRIPTION DRUG LABEL 1 71335-1763 CAPSULE 250 mg ORAL ANDA 12 sections